Stock PCVX VAXCYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
61.03 USD +0.51% Intraday chart for Vaxcyte, Inc. -0.93% -2.82%
04-25 Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing MT
04-22 Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Vaxcyte Q4 Loss Widens
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Vaxcyte Insider Sold Shares Worth $357,500, According to a Recent SEC Filing
Vaxcyte Insider Sold Shares Worth $1,980,900, According to a Recent SEC Filing
Vaxcyte Insider Sold Shares Worth $270,000, According to a Recent SEC Filing
Vaxcyte Launches Securities Offering; Shares Fall After Hours
Sector Update: Health Care Stocks Advance Monday Afternoon
Vaxcyte Shares Rise After Completion of Enrollment for Phase 1/2 Clinical Study Assessing Vaccine Candidate
Vaxcyte Completes Enrollment for Phase 1/2 Clinical Study Assessing Pneumococcal Conjugate Vaccine Candidate
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Aged 50 and Older
Vaxcyte Insider Sold Shares Worth $958,783, According to a Recent SEC Filing
Vaxcyte Insider Sold Shares Worth $485,879, According to a Recent SEC Filing
Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer
Vaxcyte Shares Drop After Clinical Pipeline Updates
Vaxcyte Insider Sold Shares Worth $828,915, According to a Recent SEC Filing
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PCVX Stock
  4. News Vaxcyte, Inc.
  5. Other languages